Home
    Registration
    Accommodation
    Topics
    Contact
Home
Welcome Note
Committees
List of Faculty
Speaker Guidelines
Timetable
Scientific Program
Anterior Segment Section
Glaucoma Section
Retina Section
Neuro-Ophthalmology
Trauma
Uveitis
New Plays in the Game
Symposia
Poster Presentations
Group A
Group B
Poster Presentation Guidelines
Registration
Invitation Letter
Accommodation
InterContinental Budapest
Sponsorship & Exhibition
Sponsors
Exhibitors
CME
General Information
Local Agent
Italian Agent
Before you travel...
About Budapest
Endorsements
Partners
Previous Congresses
COPHy 2010
COPHy 2011
COPHy 2012

  Retina Section Print

Please click on the name of the speaker to view the abstract summary
Friday, April 5, 2013
 
Retina I
Imaging and Genetics
08:30-10:00
Chairpersons: G. Coscas, France; H. Scholl, USA; E. Souied, France
08:30-09:00
Debate: Role of ICG angiography
08:30-08:40 Pro: G. Soubrane, France
08:40-08:50 Con: H. Scholl, USA
08:50-09:00
Discussion
09:00-09:30
Debate: Features in SD-OCT imaging other than retinal thickness to guide therapy
09:00-09:10 Retinal thickness sufficient: A. Augustin, Germany
09:10-09:20 No, other features important: P. Lanzetta, Italy
09:20-09:30
Discussion
09:30-10:00 Debate: role of genetics in AMD progression
09:30-09:40 Genetics play a major role in AMD progression: E. Souied, France
09:40-09:50 Genetics do not add to the morphological findings: H. Scholl, USA
09:50-10:00
 
Discussion
 
Retina II
Diabetic Macular Edema
13:30-15:00
Capsule: Diabetic macular edema - multiple optional treatments
Chairpersons: T. Lai, Hong Kong; A. Kerenyi, Hungary; J. Nemeth, Hungary
13:30-14:15
Debate: Management of center-involved DME and 20/20
13:30-13:45 Laser: F. Bandello, Italy
13:45-14:00 Anti-VEGF: S. Bressler, USA
14:00-14:15
Discussion
14:15-14:35 Debate: Management of center-involved DME and 20/50 in pseudophake?
14:15-14:25 Corticosteroids: B. Kuppermann, USA
14:25-14:35
14:35-15:00 Debate: If Ranibizumab for DME, 0.3 mg or 0.5 mg?
14:35-14:45 0.3 mg: F. Boscia, Italy
13:45-14:55 0.5 mg: U. Chakravarthy, UK
14:55-15:00
Discussion
 
Retina III
Neovascular AMD
Sponsored by an unrestricted grant from Bayer
16:45:18:30
Capsule: Management of neovascular AMD
 
Chairpersons: B. Eldem, Turkey; N. Ghazi, KSA; S. Kelly, UK; E. Souied, France
16:45-17:20
Debate: Which anti-VEGF product?
16:45-16:55 Afibercept: A. Loewenstein, Israel
16:55-17:05 Bevacizumab: U. Chakravarthy, UK
17:05:17:15 Ranibizumab: M. Battaglia Parodi, Italy
17:15-17:20
Discussion: N. Bressler, USA
17:20-17:55 Debate: Which regimen: PRN vs. Fixed regimen?
17:20-17:30 PRN regimen: P. Lanzetta, Italy
17:30-17:40 Fixed regimen: U. Chakravarthy, UK
17:40-17:50 Treat and extend: J. Mones, Spain
17:50-17:55
Discussion: S. Bressler, USA
17:55-18:15 Debate: Are post-injection antibiotics recommended?
17:55-18:05 Yes: A. Kampik, Germany
18:05-18:15 No: A. Augustin, Germany
 
18:15-18:30 Lecture: Is PCV a distinct entity from CNV?
18:15-18:25 N. Ghazi, KSA
18:25-18:30 Discussion
 
Saturday, April 6, 2013
Retina IV
Proliferative Diabetic Retinopathy
08:30-10:00
Capsule: Advancing in the treatment of PDR
Chairpersons: F. Boscia, Italy; P. Lanzetta, Italy
08:30-09:15
Debate: Management of PDR: PRP monotherapy vs. Intravitreal injections (±PRP)
08:30-08:45 PRP monotherapy: J. Cunha-Vaz, Portugal
08:45-09:00 Intravitreal injections (±PRP): F. Bandello, Italy
09:00-09:15
Discussion
09:15-10:00 Debate: Does anti-VEGF increase risk of traction retinal detachment?
09:15-09:30 Yes: A. Augustin, Germany
09:30-09:45 No: B. Eldem, Turkey
09:45-10:00
Discussion
 
Retina V
Retinal Vein Occlusion
14:30-16:00
Capsule: Management of retinal vein occlusion with macular edema
Chairpersons: G. Coscas, France; Z. Recsan, Hungary; G. Soubrane, France
14:30-15:15
Debate: Management of macular edema from branch retinal vein occlusion
14:30-14:45
14:45-15:00 Corticosteroids: B. Kuppermann, USA
15:00-15:15
Observation until worsening or no improvement: F. Boscia, Italy
15:15-16:00 Debate: Anti-VEGF drugs for macular edema from central retinal vein occlusion
15:15-15:25 Aflibercept: G. Soubrane, France
15:25-15:35 Bevacizumab: N. Ghazi, KSA
15:35-15:45 Ranibizumab: B. Eldem, Turkey
15:45-16:00
Discussion: N. Bressler, USA
Retina VI
Surgery
16:30-18:30
 
Chairpersons: I. Kovacs, Hungary; W. Mieler, USA; J. Moisseiev, Israel
16:30-17:00 Debate: New vitrectomy machines: Revolution in vitrectomy techniques or just a face-lift?
16:30-16:40 Pro, high speed small gauge vitrectomy revolutionized vitreoretinal surgery: S. Rizzo, Italy
16:40-16:50
Con, the new technologies had only a small impact on vitreoretinal surgery outcomes:
F. Boscia, Italy
16:50-17:00
Discussion
17:00-17:30 Debate: Silicone oil injection in the 21st century: Obsolete or still an important technique?
17:00-17:10 Pro, silicone oil is still an irreplaceable technique in difficult cases: A. Kampik, Germany
17:10-17:20
17:20-17:30
Discussion
17:30-18:00 Debate: The future of retinal transplantation: Technology or biology?
17:30-17:40
17:40-17:50
17:50-18:00
18:00-18:30
18:00-18:10
Debate: Vitreomacular Abnormalities
Pharmacologic Vitreomacular Adhesion Resolution in the Ocriplasmin MIVI-TRUST Program – General data
A. Augustin, Germany
18:10-18:20 Baseline Features Predictive of Pharmacologic Vitreomacular Adhesion Resolution in the Ocriplasmin MIVI-TRUST Program
B. Kuppermann, USA
18:20-18:30
 
Discussion
 

Home   
Copyright © 2008 Comtecmed.com. All rights reserved.   The website was last updated on 10/27/2013 Created by    WebStudio.co.il